Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: 2023’s top selling drugs and the COVID cliff; falling sales force Roche to reassess priorities; Phase III immunology win for Sanofi; BMS’s strong pipeline: and which companies could be acquired next.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 26 April 2024, including: 2023’s top selling drugs and the COVID cliff; falling sales force Roche Holding AG to reassess priorities; Phase III immunology win for Sanofi; Bristol Myers Squibb Company’s strong pipeline: and which companies could be acquired next.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff" - Scrip, 24 Apr, 2024.)
(Also see "Falling Sales Force New Priorities At Roche" - Scrip, 24 Apr, 2024.)
(Also see "Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib" - Scrip, 23 Apr, 2024.)
(Also see "BMS Has A Strong Pipeline, But Access Challenges Remain" - Scrip, 23 Apr, 2024.)
(Also see "Scrip M&A Podcast: Which Companies Could Be Acquired Next?" - Scrip, 23 Apr, 2024.)